Shanghai, China

Ran Xu

This inventor holds 3 USPTO granted patents and 1 EPO patent. Top assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active years: 2020-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ran Xu. Retrieved from https://idiyas.com/inventor/ran-xu-rp8xc1os

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 66.7

 

Average Co-Inventor Count = 10.2

ph-index = 1


Company Filing History:


Years Active: 2020-2022

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Ran Xu

Introduction

Ran Xu is a prominent inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that target CRTH2 receptors. With a total of three patents to his name, Xu's work is paving the way for advancements in medical treatments.

Latest Patents

One of Xu's latest patents is titled "Tricyclic compound as CRTH2 inhibitor." This patent provides a tricyclic compound, as shown in formula (I), which acts as a CRTH2 inhibitor. It also includes pharmaceutically acceptable salts, tautomers, stereoisomers, or solvates thereof, and discusses their use in treating diseases related to CRTH2 receptors. Another notable patent is for the "Crystal form of indole derivative and preparation method and use thereof." This patent discloses a crystal form of an indole derivative and a pharmaceutical composition and preparation method. The crystal form is specifically used to prepare a drug for treating diseases associated with CRTH2 receptors.

Career Highlights

Ran Xu is currently associated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. His work at this esteemed company has allowed him to focus on innovative pharmaceutical research and development. His contributions have been instrumental in advancing the understanding and treatment of diseases related to CRTH2 receptors.

Collaborations

Xu has collaborated with notable colleagues, including Bin Chen and Yuanshan Yao. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Ran Xu's innovative work in the pharmaceutical industry, particularly in the development of CRTH2 inhibitors, showcases his dedication to advancing medical science. His patents reflect a commitment to improving treatment options for patients, and his collaborations further enhance the impact of his research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…